Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 10/20 | 0.32 |
| ▸ | CDK8 | P49336 | 10/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7791830 | 0.98 | OTUD7B (0.43) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| Hydrochloric Acid SCHEMBL29770091 | 0.98 | OTUD7B (0.43) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL1429855 | 0.97 | OTUD7B (0.46) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL21584978 | 0.92 | — | — | |
| SCHEMBL6673999 | 0.90 | FKBP5 (0.39) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL2171976 | 0.90 | GRIN1 (0.40) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL5173578 | 0.87 | OTUD7B (0.37) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL9129408 | 0.87 | CRBN (0.40) | OTUD7BGRIN1GRIN2AGRIN2BCRBN | |
| SCHEMBL479513 | 0.87 | — | — | |
| SCHEMBL22958822 | 0.87 | CRBN (0.37) | OTUD7BGRIN1GRIN2AGRIN2BCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373659-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-12 | — | — | EP | claimed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | claimed |
| EP-4714942-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC Corporation (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4188093-B9 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORP (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4646271-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4188093-B1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | BEBETTER MED INC. (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMA (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024148150-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-2035379-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2007131764-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | OTUD7B 2885/4885GRIN1 3143/4885GRIN2A 3590/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | OTUD7B 3768/4885GRIN1 1/4885GRIN2A 8/4885 |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | CYP46A1, CYP4A22, CYP2C19 | OTUD7B 1529/4885GRIN1 1999/4885GRIN2A 2517/4885 |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | OTUD7B 1819/4885GRIN1 294/4885GRIN2A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.